Skip to content
10-Q

Quarterly Report

ASSERTIO THERAPEUTICS, INC.

0001005201-20-000035

← back to feed
Filed
May 11, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · May 6, 2020 81.38M sh
Shares Diluted Q1 2020 · Mar 31, 2020 71.05M sh
Shares Diluted Q1 2020 · Mar 31, 2019 64.24M sh
Capex Q1 2020 · Mar 31, 2020 $9K
Capex Q1 2020 · Mar 31, 2019 $13K
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$25.06M
Operating Cash Flow Q1 2020 · Mar 31, 2019 $27.2M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $105.97M
Cash And Equivalents Q1 2020 · Dec 31, 2019 $42.11M
Stockholders Equity Q1 2020 · Mar 31, 2020 $84.04M
Stockholders Equity Q1 2020 · Dec 31, 2019 $57.96M
Stockholders Equity Q1 2020 · Mar 31, 2019 $208.55M
Stockholders Equity Q1 2020 · Dec 31, 2018 $220.34M
Current Liabilities Q1 2020 · Mar 31, 2020 $122.29M
Current Liabilities Q1 2020 · Dec 31, 2019 $184.55M
Total Liabilities Q1 2020 · Mar 31, 2020 $135.24M
Total Liabilities Q1 2020 · Dec 31, 2019 $469.21M
Current Assets Q1 2020 · Mar 31, 2020 $180.11M
Current Assets Q1 2020 · Dec 31, 2019 $103.95M
Total Assets Q1 2020 · Mar 31, 2020 $219.27M
Total Assets Q1 2020 · Dec 31, 2019 $527.17M
Eps Diluted Q1 2020 · Mar 31, 2020 $0.58
Eps Diluted Q1 2020 · Mar 31, 2019 −$0.22
Eps Basic Q1 2020 · Mar 31, 2020 $0.58
Eps Basic Q1 2020 · Mar 31, 2019 −$0.22
Sga Expense Q1 2020 · Mar 31, 2020 $27.31M
Sga Expense Q1 2020 · Mar 31, 2019 $25.05M
Net Income Q1 2020 · Mar 31, 2020 $41.23M
Net Income Q1 2020 · Mar 31, 2019 −$14.3M
Operating Income Q1 2020 · Mar 31, 2020 −$16.63M
Operating Income Q1 2020 · Mar 31, 2019 $3.07M
Revenue Q1 2020 · Mar 31, 2020 $20.92M
Revenue Q1 2020 · Mar 31, 2019 $57.93M